title: Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST).
abstract: Patient adherence to therapy is essential to assess treatment efficacy, particularly in clinical trials. Active treatment usually is expected to benefit patients. The healthy adherer effect, the association or greater adherence to all health-promoting behaviors, including medication and overall concern for health, explains the improved survival of more adherent patients in both active and placebo medication groups of several clinical trials. The Cardiac Arrhythmia Suppression Trial (CAST), a placebo-controlled double-blind clinical trial of post-myocardial infarction (MI) patients with asymptomatic ventricular arrhythmias, in which active medication (encainide or flecainide) led to increased mortality, provided an opportunity to examine the relationship of adherence to survival from a different perspective. We consider whether adherence to active treatment was related to arrhythmic mortality and whether a healthy adherer effect might counteract the effect of treatment on mortality among patients taking active medication. Adherence (average pill count) at the first follow-up visit did not differ in the active treatment (92.2%, standard deviation (SD) = 11.97, n = 574) and placebo (90.8%, SD = 13.66, n = 579) groups. In a Cox proportional hazard regression model, medication adherence predicted arrhythmic mortality among the active (P < 0.0062) but not the placebo medication group. The effect of adherence on arrhythmic mortality was significant beyond the effects of ejection fraction, race, spouse, smoking status, diuretic medication, and history of MI. A 10% increase in adherence led to more than a threefold increase of risk of arrhythmic death. The design of the CAST, which included a titration phase, may have tended to select relatively adherent patients since only those whose arrhythmias were suppressed with active medication were randomized into the trial. The data do not support a strong healthy adherer effect in the CAST. There was no evidence in this study that a healthy adherer effect counterbalanced the effect of the active medication.
authors.affiliation: Washington Hospital Center, Washington, DC, USA.
authors.forename: D
authors.initials: D
authors.lastname: Obias-Manno
authors.forename: E
authors.initials: E
authors.lastname: Friedmann
authors.forename: M M
authors.initials: MM
authors.lastname: Brooks
authors.forename: S A
authors.initials: SA
authors.lastname: Thomas
authors.forename: C
authors.initials: C
authors.lastname: Haakenson
authors.forename: M
authors.initials: M
authors.lastname: Morris
authors.forename: F
authors.initials: F
authors.lastname: Wimbush
authors.forename: C
authors.initials: C
authors.lastname: Somelofski
authors.forename: F
authors.initials: F
authors.lastname: Goldner
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000401:mortality*; D016700:Encainide / Q000009:adverse effects; D005260:Female; D005424:Flecainide / Q000009:adverse effects; D015438:Health Behavior; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance
chemical_list: D000889:Anti-Arrhythmia Agents; D005424:Flecainide; D016700:Encainide